This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Salk Institute for Biological Studies, la jolla, CA, United States ...
1Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain. 2Department of ...
3Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. *Corresponding Author: David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
1Northwestern University, Chicago, Illinois.
1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
NCI Director W. Kimryn Rathmell, MD, PhD, announced today that she will step down effective Monday, January 20, the same day Donald Trump will be inaugurated as president. Rathmell, who had previously ...
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
1Division of Solid Tumor Oncology, Memorial Sloan Kettering, New York, New York. *Corresponding Author: Luis A. Diaz Jr, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E ...
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee. *Corresponding Author: Brent A. Orr, Department of Pathology, St. Jude Children ...
Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...
1Department of Biology, University of Rochester, Rochester, New York. Search for other works by this author on: 2Westlake Disease Modeling Lab, Westlake Laboratory of Life Sciences and Biomedicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback